BIAL - PORTELA & CA. S.A. et al v. Hetero Labs Limited et al > Summary
Court Case Number 1:20-cv-00780
Filing Date Jun 9, 2020
Termination Date Jul 29, 2020
Court Delaware District Court
Status Judgment - Judgment on Consent
Defendant
Plaintiff Attorneys
15Sunovion Pharmaceuticals
Attorney Name: Karen Ann Jacobs
Morris Nichols Arsht & Tunnell
Sunovion Pharmaceuticals
Attorney Name: Steven J. Balick
Ashby & Geddes
Sunovion Pharmaceuticals
Attorney Name: Andrew C. Mayo
Ashby & Geddes
Sunovion Pharmaceuticals
Attorney Name: James B. Monroe
Finnegan, Henderson, Farabow, Garrett & Dunner
Sunovion Pharmaceuticals
Attorney Name: Jennifer H. Roscetti
Finnegan, Henderson, Farabow, Garrett & Dunner
Sunovion Pharmaceuticals
Attorney Name: Charles T. Collins-Chase
Finnegan, Henderson, Farabow, Garrett & Dunner
Sunovion Pharmaceuticals
Attorney Name: Lauren J. Robinson
Finnegan, Henderson, Farabow, Garrett & Dunner
Sunovion Pharmaceuticals
Attorney Name: Danielle C. Pfifferling
Finnegan, Henderson, Farabow, Garrett & Dunner
Sunovion Pharmaceuticals
Attorney Name: Meredith H. Boerschlein
Finnegan, Henderson, Farabow, Garrett & Dunner
Bial
Attorney Name: Steven J. Balick
Ashby & Geddes
Bial
Attorney Name: Andrew C. Mayo
Ashby & Geddes
Bial - Holding, S.A.
Attorney Name: Steven J. Balick
Ashby & Geddes
Bial - Holding, S.A.
Attorney Name: Andrew C. Mayo
Ashby & Geddes
Sunovion Pharmaceuticals
Attorney Name: Jennifer O. Ying
Morris Nichols Arsht & Tunnell
Defendant Attorneys
Hetero
Attorney Name: David E. Moore
Potter Anderson & Corroon
Cause
35:271 Patent Infringement
Related Patents
| Doc No | Title | Issue date |
|---|---|---|
| 10702536 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | Jul 7, 2020 |
| 10695354 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | Jun 30, 2020 |
| 10675287 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | Jun 9, 2020 |
| 05753646 | Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them | May 19, 1998 |
